Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In patients suffering from anorexia nervosa associated with severe major depression, serotonin reuptake inhibitor drugs have shown little efficacy in significantly reducing depressive symptoms. A possible explanation for this poor efficacy could be that people with anorexia nervosa have a deficiency in amino acids such as tryptophan, which is necessary for the production of the neurotransmitter serotonin. Therefore, tryptophan supplementation has been suggested as a means of increasing the pharmacological response to serotonin reuptake inhibitor drugs in patients with anorexia nervosa. Furthermore, malnutrition present in patients suffering from anorexia nervosa is in some cases associated with problems of intestinal absorption of nutrients, with possible implications on the pharmacokinetics of the drugs administered, including selective serotonin reuptake inhibitors (SSRIs).
The present observational study aims to evaluate the correlations between the clinical response to Citalopram therapy (in different o.s. and i.v. formulations) and some nutritional, neurotransmitter and inflammatory biomarkers, in order to identify potential predictive markers of response to therapy for severe major depression in patients with anorexia nervosa.
The following parameters will be evaluated in patients enrolled in all 3 observation times described above:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A: Citalopram i.v. and p.o | Both intravenous and oral administration of citalopram |
| |
| Group B: Citalopram p.o | Oral administration of citalopram |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Citalopram i.v. and p.o | Drug | Citalopram: i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Hamilton Depression Rating Scale | 17-item Hamilton Depression Rating Scale - | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
| Change in plasma level of citalopram | Plasma level of citalopram | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
| Change in plasma level of dopamine | Plasma level of dopamine | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
| Change in serum level of serotonin | Serum level of serotonin | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
| Change in serum level of brain-derived neurotrophic factor | Serum level of brain-derived neurotrophic factor | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
| Change in serum level of tryptophan | Serum level of tryptophan | At baseline, 2 weeks and 4 weeks after treatment with citalopram |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with anorexia nervosa and severe depression
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Riccardo Cremascoli, MD | Contact | +393497292068 | r.cremascoli@auxologico.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istituto Auxologico Italiano | Recruiting | Oggebbio | Italy |
Not provided
| ID | Term |
|---|---|
| D000856 | Anorexia Nervosa |
| D003865 | Depressive Disorder, Major |
| ID | Term |
|---|---|
| D001068 | Feeding and Eating Disorders |
| D001523 | Mental Disorders |
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| Citalopram p.o | Drug | Citalopram: p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28 |
|